Novel paradigms for drug discovery: computational multitarget screening

Trends in Pharmacological Sciences

Volumn 29, Issue 2, 2008, Pages 62-71

  Jenwitheesuk, Ekachai ^a,b   Horst, Jeremy A ^a,c   Rivas, Kasey L ^a   Van Voorhis, Wesley C ^a   Samudrala, Ram ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMPHOTERICIN B; CHLOROQUINE; COTRIMOXAZOLE; CURCUMIN; CYCLOSPORIN A; ENVIROXIME; FUMAGILLIN; HYDROXYCHLOROQUINE; IMATINIB; MINOCYCLINE; PROTEIN INHIBITOR; SURAMIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALGORITHM; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COST BENEFIT ANALYSIS; DRUG BINDING; DRUG INHIBITION; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MALARIA FALCIPARUM; MATHEMATICAL COMPUTING; NONHUMAN; OPPORTUNISTIC INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; VIRTUAL REALITY;

ANIMALS; ANTI-HIV AGENTS; ANTIMALARIALS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HIV-1; HUMANS; PLASMODIUM FALCIPARUM;

EID: 39049114500     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.11.007     Document Type: Article

References (107)

1. Hammer S.M., et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-U. S. A. panel. J. Am. Med. Assoc. 296 (2006) 827-843
2. Volberding P.A., et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N. Engl. J. Med. 333 (1995) 401-407
3. Rusconi S., et al. Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people. Antivir. Ther. 1 (1996) 211-219
4. Metzner K.J., et al. Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients. AIDS 21 (2007) 703-711
5. Jones R., and Gazzard B. The cost of antiretroviral drugs and influence on prescribing policies. Int. J. STD AIDS 17 (2006) 499-506
6. Bisson G.P., et al. Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 20 (2006) 1333-1336
7. Moya J., et al. Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimen. HIV Clin. Trials 7 (2006) 210-214
8. Faivre S., et al. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 671-688
9. Millan M.J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur. J. Pharmacol. 500 (2004) 371-384
10. Wong M.L., et al. Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14241-14246
11. Celotti F., and Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol. Res. 43 (2001) 429-436
12. Bugatti A., et al. Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of HIV-1 Tat and gp120 proteins. Antimicrob. Agents Chemother. 51 (2007) 2337-2345
13. Litovchick A., et al. Neomycin B-arginine conjugate, a novel HIV-1 Tat antagonist: synthesis and anti-HIV activities. Biochemistry 40 (2001) 15612-15623
14. Santhosh K.C., et al. Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. J. Med. Chem. 44 (2001) 703-714
15. Kuchimanchi K.R., et al. Binding of cosalane-a novel highly lipophilic anti-HIV agent-to albumin and glycoprotein. J. Pharm. Sci. 90 (2001) 659-666
16. De Clercq E. New developments in anti-HIV chemotherapy. Curr. Med. Chem. 8 (2001) 1543-1572
17. Casimiro-Garcia A., et al. Synthesis and anti-HIV activity of cosalane analogues incorporating nitrogen in the linker chain. Bioorg. Med. Chem. 8 (2000) 191-200
18. Cushman M., et al. Cosalane analogues with enhanced potencies as inhibitors of HIV-1 protease and integrase. J. Med. Chem. 38 (1995) 443-452
19. Cushman M., et al. Design, synthesis, and biological evaluation of cosalane, a novel anti-HIV agent which inhibits multiple features of virus reproduction. J. Med. Chem. 37 (1994) 3040-3050
20. Shoichet B.K. Virtual screening of chemical libraries. Nature 432 (2004) 862-865
21. Jenkins J.L., et al. Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin. Proteins 50 (2003) 81-93
22. Mestres J. Virtual screening: a real screening complement to high-throughput screening. Biochem. Soc. Trans. 30 (2002) 797-799
23. Jenwitheesuk E., and Samudrala R. Identification of potential multitarget antimalarial drugs. J. Am. Med. Assoc. 294 (2005) 1490-1491
24. Jenwitheesuk E., and Samudrala R. Improved prediction of HIV-1 protease-inhibitor binding energies by molecular dynamics simulations. BMC Struct. Biol. 3 (2003) 2
25. Jenwitheesuk E., et al. Improved accuracy of HIV-1 genotypic susceptibility interpretation using a consensus approach. AIDS 18 (2004) 1858-1859
26. Jenwitheesuk E., and Samudrala R. Prediction of HIV-1 protease inhibitor resistance using a protein-inhibitor flexible docking approach. Antivir. Ther. 10 (2005) 157-166
27. Jenwitheesuk E., et al. PIRSpred: a web server for reliable HIV-1 protein-inhibitor resistance/susceptibility prediction. Trends Microbiol. 13 (2005) 150-151
28. Jenwitheesuk E., and Samudrala R. Identification of potential HIV-1 targets of minocycline. Bioinformatics 23 (2007) 2797-2799
29. Rao S., and Rossmann M. Comparison of super-secondary structures in proteins. J. Mol. Biol. 76 (1973) 241-256
30. Scheeff E., and Bourne P. Structural evolution of the protein kinase-like superfamily. PLoS Comput. Biol. 1 (2005) e49
31. Hopkins A.L., et al. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 16 (2006) 127-136
32. Wierenga R.K. The TIM-barrel fold: a versatile framework for efficient enzymes. FEBS Lett. 492 (2001) 193-198
33. Hubbard T.J., et al. SCOP: a structural classification of proteins database. Nucleic Acids Res. 25 (1997) 236-239
34. Kovacs J.A., and Masur H. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection. N. Engl. J. Med. 342 (2000) 1416-1429
35. Pitter C., et al. Cost-effectiveness of cotrimoxazole prophylaxis among persons with HIV in Uganda. J. Acquir. Immune Defic. Syndr. 44 (2007) 336-343
36. Clemente J.C., et al. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Acta Crystallogr. D Biol. Crystallogr. 62 (2006) 246-252
37. Wondrak E.M., et al. Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs. J. Antimicrob. Chemother. 21 (1988) 151-161
38. Lemaitre M., et al. Protective activity of tetracycline analogs against the cytopathic effect of the human immunodeficiency viruses in CEM cells. Res. Virol. 141 (1990) 5-16
39. Desai P.V., et al. Identification of novel parasitic cysteine protease inhibitors by use of virtual screening. 2. The available chemical directory. J. Med. Chem. 49 (2006) 1576-1584
40. Desai P.V., et al. Identification of novel parasitic cysteine protease inhibitors using virtual screening. 1. The ChemBridge database. J. Med. Chem. 47 (2004) 6609-6615
41. Chong C.R., et al. A clinical drug library screen identifies astemizole as an antimalarial agent. Nat. Chem. Biol. 2 (2006) 415-416
42. Weisman J.L., et al. Searching for new antimalarial therapeutics amongst known drugs. Chem. Biol. Drug Des. 67 (2006) 409-416
43. Barratt M.D. Prediction of toxicity from chemical structure. Cell Biol. Toxicol. 16 (2000) 1-13
44. Benigni R., and Zito R. Designing safer drugs: (Q)SAR-based identification of mutagens and carcinogens. Curr. Top. Med. Chem. 3 (2003) 1289-1300
45. Dearden J.C. In silico prediction of drug toxicity. J. Comput. Aided Mol. Des. 17 (2003) 119-127
46. Greene N. Computer systems for the prediction of toxicity: an update. Adv. Drug Deliv. Rev. 54 (2002) 417-431
47. Roche O., and Guba W. Computational chemistry as an integral component of lead generation. Mini Rev. Med. Chem. 5 (2005) 677-683
48. Swamidass S.J., et al. Kernels for small molecules and the prediction of mutagenicity, toxicity and anti-cancer activity. Bioinformatics 21 Suppl 1 (2005) i359-i368
49. Zmuidinavicius D., et al. Progress in toxinformatics: the challenge of predicting acute toxicity. Curr. Top. Med. Chem. 3 (2003) 1301-1314
50. Wexler P. TOXNET: the National Library of Medicine's toxicology database. Am. Fam. Physician 52 (1995) 1677-1678
51. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today 6 (2001) 357-366
52. Vidal D., et al. A novel search engine for virtual screening of very large databases. J. Chem. Inf. Model. 46 (2006) 836-843
53. Chen Y.Z., and Ung C.Y. Computer automated prediction of potential therapeutic and toxicity protein targets of bioactive compounds from Chinese medicinal plants. Am. J. Chin. Med. 30 (2002) 139-154
54. Al Omari A., and Murry D.J. Pharmacogenetics of the cytochrome P450 enzyme system: review of current knowledge and clinical significance. J. Pharm. Pract. 20 (2007) 206-218
55. Pereira F.B., et al. Membrane fusion induced by the HIV type 1 fusion peptide: modulation by factors affecting glycoprotein 41 activity and potential anti-HIV compounds. AIDS Res. Hum. Retroviruses 13 (1997) 1203-1211
56. Oki T., et al. Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities. J. Antibiot. (Tokyo) 43 (1990) 763-770
57. Utz J.P. Systemic fungal infections amenable to chemotherapy. Dis. Mon. 35 (1963) 1-52
58. Tzatzarakis M.N., et al. Comparison of in vitro activities of amphotericin, clotrimazole, econazole, miconazole, and nystatin against Fusarium oxysporum. J. Environ. Sci. Health B 36 (2001) 331-340
59. Kessler H.A., et al. Effects of amphotericin B on hepatitis B virus. Antimicrob. Agents Chemother. 20 (1981) 826-833
60. Kohler S., et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. 44 (2000) 1850-1854
61. Fesen M.R., et al. Inhibitors of human immunodeficiency virus integrase. Proc. Natl. Acad. Sci. U. S. A. 90 (1993) 2399-2403
62. Levitz S.M., et al. Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation. J. Clin. Invest. 100 (1997) 1640-1646
63. Tsai W.P., et al. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res. Hum. Retroviruses 6 (1990) 481-489
64. Crowle A.J., and May M.H. Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3. Antimicrob. Agents Chemother. 34 (1990) 2217-2222
65. Jiang M.C., et al. Inhibition of HIV-1 Tat-mediated transactivation by quinacrine and chloroquine. Biochem. Biophys. Res. Commun. 226 (1996) 1-7
66. Ang K.K., et al. In vivo antimalarial activity of the beta-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. 44 (2000) 1645-1649
67. Fivelman Q.L., et al. The effect of artesunate combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. Trans. R. Soc. Trop. Med. Hyg. 93 (1999) 429-432
68. Mackenzie A.H. An appraisal of chloroquine. Arthritis Rheum. 13 (1970) 280-291
69. Artico M., et al. Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. J. Med. Chem. 41 (1998) 3948-3960
70. Yang F., et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280 (2005) 5892-5901
71. Hooker C.W., et al. Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. J. Virol. 75 (2001) 3095-3104
72. Li M., et al. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res. 67 (2007) 1988-1996
73. Srivastava K.C., et al. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prostaglandins Leukot. Essent. Fatty Acids 52 (1995) 223-227
74. Braaten D., et al. Cyclosporine A-resistant human immunodeficiency virus type 1 mutants demonstrate that Gag encodes the functional target of cyclophilin A. J. Virol. 70 (1996) 5170-5176
75. Onyewu C., et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei. Antimicrob. Agents Chemother. 47 (2003) 956-964
76. Odom A., et al. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob. Agents Chemother. 41 (1997) 156-161
77. Perkins M.E., et al. Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum. Antimicrob. Agents Chemother. 42 (1998) 843-848
78. Nakagawa M., et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem. Biophys. Res. Commun. 313 (2004) 42-47
79. Silverman J.A., et al. Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology. Antimicrob. Agents Chemother. 41 (1997) 1859-1866
80. Damaso C.R., and Moussatche N. Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins. J. Gen. Virol. 79 (1998) 339-346
81. Jayasuriya H., et al. Durhamycin A, a potent inhibitor of HIV Tat transactivation. J. Nat. Prod. 65 (2002) 1091-1095
82. Gordon M.A., and Lapa E.W. Durhamycin, a Pentaene Antifungal Antibiotic from Streptomyces durhamensis sp. n. Appl. Microbiol. 14 (1966) 754-760
83. http://dtp.nci.nih.gov (2007)
84. Nikolaeva L., and Galabov A.S. Antiviral effect of the combination of enviroxime and disoxaril on coxsackievirus B1 infection. Acta Virol. 44 (2000) 73-78
85. Ninomiya Y., et al. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides. Antiviral Res. 13 (1990) 61-74
86. Nikolaeva L., and Galabov A.S. Synergistic inhibitory effect of enviroxime and disoxaril on poliovirus type 1 replication. Acta Virol. 39 (1995) 235-241
87. Watanabe N., et al. Fumagillin suppresses HIV-1 infection of macrophages through the inhibition of Vpr activity. FEBS Lett. 580 (2006) 2598-2602
88. Franssen F.F., et al. Susceptibility of Encephalitozoon cuniculi to several drugs in vitro. Antimicrob. Agents Chemother. 39 (1995) 1265-1268
89. Didier E.S. Effects of albendazole, fumagillin, and TNP-470 on microsporidial replication in vitro. Antimicrob. Agents Chemother. 41 (1997) 1541-1546
90. Molina J.M., et al. Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study. The French Microsporidiosis Study Group. AIDS 11 (1997) 1603-1610
91. Zhang P., et al. Angiogenesis inhibitors specific for methionine aminopeptidase 2 as drugs for malaria and leishmaniasis. J. Biomed. Sci. 9 (2002) 34-40
92. Warhurst D.C., et al. Hydroxychloroquine is much less active than chloroquine against chloroquine-resistant Plasmodium falciparum, in agreement with its physicochemical properties. J. Antimicrob. Chemother. 52 (2003) 188-193
93. Sperber K., et al. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res. Hum. Retroviruses 9 (1993) 91-98
94. Mimoto T., et al. Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine. J. Med. Chem. 42 (1999) 1789-1802
95. Giacometti A., et al. In-vitro activity of macrolides alone and in combination with artemisin, atovaquone, dapsone, minocycline or pyrimethamine against Cryptosporidium parvum. J. Antimicrob. Chemother. 38 (1996) 399-408
96. Boucher H.W., et al. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob. Agents Chemother. 44 (2000) 2225-2229
97. Wallace Jr. R.J., et al. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 46 (2002) 3164-3167
98. Collins L., and Franzblau S.G. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41 (1997) 1004-1009
99. Arai S., et al. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 36 (1992) 1322-1324
100. Chang H.R., et al. Activity of minocycline against Toxoplasma gondii infection in mice. J. Antimicrob. Chemother. 27 (1991) 639-645
101. Yahi N., et al. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells. J. Biol. Chem. 269 (1994) 24349-24353
102. Baba M., et al. Selective inhibition of human cytomegalovirus replication by naphthalenedisulfonic acid derivatives. Antiviral Res. 20 (1993) 223-233
103. Tewtrakul S., et al. HIV-1 integrase inhibitory substances from Coleus parvifolius. Phytother. Res. 17 (2003) 232-239
104. Aguilar J.S., et al. The polysulfonated compound suramin blocks adsorption and lateral difusion of herpes simplex virus type-1 in vero cells. Virology 258 (1999) 141-151
105. Debyser Z., et al. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 1451-1455
106. Hui E.K., and Nayak D.P. Role of G protein and protein kinase signalling in influenza virus budding in MDCK cells. J. Gen. Virol. 83 (2002) 3055-3066
107. Crance J.M., et al. Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds. Res. Virol. 148 (1997) 353-365